Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Diagnosis Clear all
Completed Not applicable Interventional Results available

Improving Visual Attention in Schizophrenia

NCT03880227
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Active anodal tDCS, Sham tDCS
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

NCT00588731
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

NCT04559529
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam (LEV) 500 mg, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs

NCT04748679
View directory record Official record
Conditions
Schizophrenia; Psychosis, Persecutory Delusion
Interventions
Worry Intervention, Befriending
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 3 Interventional

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

NCT01979679
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 80 mg, Lurasidone 120 mg, Lurasidone 160 mg
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Minocycline and Tobacco Craving in Smokers With Schizophrenia

NCT02968602
View directory record Official record
Conditions
Schizophrenia, Tobacco Use
Interventions
Minocycline, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Oxytocin Study

NCT02577575
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk

NCT01923701
View directory record Official record
Conditions
ARMS, APS, Prodromal Symptoms
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

NCT00161031
View directory record Official record
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jun 10, 2026, 7:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia

NCT01620086
View directory record Official record
Conditions
Schizophrenia
Interventions
Active Repetitive Transcranial Magnetic Stimulation 1 Hz, Active Repetitive Transcranial Magnetic Stimulation 10 Hz, Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz, Sham control site Repetitive Transcranial Magnetic Stimulation, Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional

Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy

NCT00791440
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Cognitive-Behavior Therapy, Standard Psychiatric Treatment
Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jun 10, 2026, 7:29 AM EDT
Recruiting Not applicable Interventional

iTBS to Enhance Social Cognition in People With Psychosis

NCT06118268
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
Interventions
iTBS (Active), iTBS (Sham)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 10, 2026, 7:29 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

NCT05184335
View directory record Official record
Conditions
Schizophrenia
Interventions
Brilaroxazine, Placebo
Drug · Other
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
690 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

NCT02687984
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Garden Grove, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jun 10, 2026, 7:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Jun 10, 2026, 7:29 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jun 10, 2026, 7:29 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cardio Risk of Acute Schizophrenia Olanzapine Duke

NCT00672464
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Metformin, Simvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Culturally Responsive Person-Centered Care for Psychosis

NCT00231933
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Person-centered planning (PCP), Community integration (CI), Illness management recovery (IMR)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

NCT03465371
View directory record Official record
Conditions
Psychosis
Interventions
CSC OnDemand Training Intervention, InPerson Intervention, Virtual InPerson Intervention
Other
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jun 10, 2026, 7:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Receptors and Schizophrenia

NCT00952393
View directory record Official record
Conditions
Schizophrenia
Interventions
Pharmacokinetic
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Jun 10, 2026, 7:29 AM EDT